Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT-008 in Meibomian Gland Dysfunction
NCT05261386Phase 2Completed
- Sponsor
- Cloudbreak Pharma
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CBT-008 in meibomian gland dysfunction (MGD) (3 arms), sponsored by Cloudbreak Pharma. Primary endpoints: Intraocular Pressure at 4 weeks, Ocular Discomfort Score at 4 weeks and 1 more. Started Mar 2022; status: completed.
02
Drugs
CBT-008
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT05261386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261386.